by my maths - USD $20 shareprice is about 20k patients a month or about $US4mio of rev per month (depending on what rev multiple we use) lets go with 30x revenue.
So 20k patients at US$195 per month = US$3,900,000 rev x12 = US$46.8mio per annum x30 for the rev multiple = US$1.404mio market cap divided by 60,521,648 shares on issue (obviously pending final cap raise and shares issued) = US$23.2 share price
So its not out of this world - my best guess is that current monitoring of patients is between 7,000 and 10,000 a month and but cant get a decent read on how we are tracking but that should clear up in the next couple months - hopefully an update from the company soon.
Keep in mind an additional 7 university hospitals should give another boost to monitoring. Growth rate in revenue to achieve USD 11mio from USD 2.2mio in the first quarter is impressive....so incremental additions of hospitals gives incremental increases to recurring revenue - very attractive to investors and should command a higher multiple than device sales et al
It not out of this world $20 in the next 6-12months
